GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » EV-to-EBITDA

Defence Therapeutics (XCNQ:DTC) EV-to-EBITDA : -5.24 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Defence Therapeutics's enterprise value is C$60.69 Mil. Defence Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-11.58 Mil. Therefore, Defence Therapeutics's EV-to-EBITDA for today is -5.24.

The historical rank and industry rank for Defence Therapeutics's EV-to-EBITDA or its related term are showing as below:

XCNQ:DTC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -94.06   Med: 0   Max: 0
Current: -5.24

XCNQ:DTC's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs XCNQ:DTC: -5.24

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Defence Therapeutics's stock price is C$1.31. Defence Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.270. Therefore, Defence Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Defence Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Defence Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics EV-to-EBITDA Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
EV-to-EBITDA
- -84.94 -9.94

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.52 -13.37 -20.27 -21.00 -9.05

Competitive Comparison of Defence Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Defence Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Defence Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's EV-to-EBITDA falls into.



Defence Therapeutics EV-to-EBITDA Calculation

Defence Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=60.685/-11.577
=-5.24

Defence Therapeutics's current Enterprise Value is C$60.69 Mil.
Defence Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-11.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Defence Therapeutics  (XCNQ:DTC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Defence Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.31/-0.270
=At Loss

Defence Therapeutics's share price for today is C$1.31.
Defence Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.270.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Defence Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.